Literature DB >> 17433968

The prognostic value of anaemia at different treatment times in patients with locally advanced head and neck cancer treated with surgery and postoperative radiotherapy.

B Dietl1, J Marienhagen, C Schäfer, O Kölbl.   

Abstract

AIMS: We report a retrospective mono-institutional analysis of anaemia (< 12 g/dl) at different treatment times (preoperative, postoperative, before radiotherapy and nadir levels during radiotherapy) in head and neck cancer patients treated with surgery and postoperative radiotherapy. The study objective was to determine whether, and at which time points, anaemia had a significant effect on the end points overall survival and local recurrence-free survival (LRFS).
MATERIALS AND METHODS: The end points for the statistical analysis in 130 patients were LRFS and overall survival. A univariate analysis (Log-rank test) was carried out on the following variables with potential end point-related impact: gender, T, N, G, American Joint Committee on Cancer (AJCC) stage, tumour site, resection status, overall treatment time (OTT), radiotherapy treatment time (RTT) and preoperative, postoperative, pre-radiotherapy and nadir levels of haemoglobin during radiotherapy. Individual variables with a significant effect (P=0.05) were then subjected to multivariate Cox regression analysis.
RESULTS: The median overall survival was 59 months. The univariate analysis showed that AJCC stage (P=0.0268), resection status (P=0.0407), preoperative haemoglobin level (P=0.0087), postoperative haemoglobin level (P=0.0035), RTT (P=0.0042) and OTT (P=0.0343) significantly influenced overall survival. OTT (P=0.0130) and postoperative haemoglobin (P=0.0243) had a significant effect on LRFS. The multivariate Cox regression analysis showed postoperative haemoglobin < 12 g/dl and OTT>100 days to be independent negative prognostic factors for both end points.
CONCLUSIONS: Postoperative acute anaemia < 12 g/dl and an OTT>100 days were independent negative prognostic factors for LRFS and overall survival in patients with head and neck cancer treated with surgery and postoperative radiotherapy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17433968     DOI: 10.1016/j.clon.2007.02.009

Source DB:  PubMed          Journal:  Clin Oncol (R Coll Radiol)        ISSN: 0936-6555            Impact factor:   4.126


  6 in total

1.  Prognostic factors in patients with locally advanced head and neck cancer treated with concurrent radiochemotherapy.

Authors:  Davide Franceschini; Fabiola Paiar; Calogero Saieva; Pierluigi Bonomo; Benedetta Agresti; Icro Meattini; Daniela Greto; Monica Mangoni; Fiammetta Meacci; Mauro Loi; Giacomo Zei; Lorenzo Livi; Giampaolo Biti
Journal:  Radiol Med       Date:  2015-09-24       Impact factor: 3.469

Review 2.  Role of hyperoxic treatment in cancer.

Authors:  Sei W Kim; In K Kim; Sang H Lee
Journal:  Exp Biol Med (Maywood)       Date:  2020-04-23

3.  Definitive Radiotherapy versus Postoperative Radiotherapy of Patients with Oro- and Hypopharyngeal Cancer: Impact of Prognostic Factors.

Authors:  Volker Rudat; Salia Ahmet-Osman; Oliver Schramm; Andreas Dietz
Journal:  J Oncol       Date:  2012-01-18       Impact factor: 4.375

Review 4.  Current relevance of hypoxia in head and neck cancer.

Authors:  Marius G Bredell; Jutta Ernst; Ilhem El-Kochairi; Yuliya Dahlem; Kristian Ikenberg; Desiree M Schumann
Journal:  Oncotarget       Date:  2016-08-02

5.  Ultrasonographic assessment of renal perfusion in bitches with mammary carcinoma treated with long-term carprofen.

Authors:  Cristhian Rene Vargas Estrada; Bruna Fernanda Firmo; Daniele Belchior Vela; Marjury Cristina Maronezi; Ricardo Andrés Ramirez Uscategui; Beatriz Gasser; Marcus Antônio Rossi Feliciano; Letícia Pavan; Luiz Paulo Nogueira Aires; Gabriela Piovan Lima; Andrigo Barboza De Nardi
Journal:  Sci Rep       Date:  2021-12-02       Impact factor: 4.379

6.  A retrospective study: the prognostic value of anemia, smoking and drinking in esophageal squamous cell carcinoma with primary radiotherapy.

Authors:  Fang Zhang; Hui Han; Chuansheng Wang; Jianbo Wang; Guangyu Zhang; Fangli Cao; Yufeng Cheng
Journal:  World J Surg Oncol       Date:  2013-10-01       Impact factor: 2.754

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.